Journal
CNS DRUGS
Volume 29, Issue 6, Pages 453-463Publisher
ADIS INT LTD
DOI: 10.1007/s40263-015-0252-0
Keywords
-
Categories
Funding
- Mosbacher Family Fund for Autism Research
- National Institute of Child Health and Human Development
- American Academy of Child and Adolescent Psychiatry
- Department of Psychiatry and Behavioral Sciences
- Bristol-Myers Squibb
- Roche
- Forest
- IntegraGen
Ask authors/readers for more resources
Pharmacologic treatments targeting specific molecular mechanisms relevant for autism spectrum disorder (ASD) are beginning to emerge in early drug development. This article reviews the evidence for the disruption of glutamatergic neurotransmission in animal models of social deficits and summarizes key pre-clinical and clinical efforts in developing pharmacologic interventions based on modulation of glutamatergic systems in individuals with ASD. Understanding the pathobiology of the glutamatergic system has led to the development of new investigational treatments for individuals with ASD. Specific examples of medications that modulate the glutamatergic system in pre-clinical and clinical studies are described. Finally, we discuss the limitations of current strategies and future opportunities in developing medications targeting the glutamatergic system for treating individuals with ASD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available